A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre- S2 particles for revaccination of healthy adult nonresponders

Joseph S. Bertino; Paul Tirrell; Richard N. Greenberg; Harry L. Keyserling; Gregory A. Poland; Dieter Gump; Mary Lou Kumar; Keith Ramsey

doi:10.1093/infdis/175.3.678

A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S₁, and pre- S₂ particles for revaccination of healthy adult nonresponders

Joseph S. Bertino, Paul Tirrell, Richard N. Greenberg, Harry L. Keyserling, Gregory A. Poland, Dieter Gump, Mary Lou Kumar, Keith Ramsey

Internal Medicine

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Abstract

The efficacy of 10-μg and 40-μg hepatitis B vaccines was compared with that of an investigational vaccine containing pre-S₁, pre-S₂, and S subunit particles (mixed particle vaccine) in inducing protective anti-hepatitis B surface antigen (anti-HBs) concentrations in 46 otherwise healthy persons who previously did not develop measurable levels of antibodies to at least one complete course of vaccine. A statistically significant difference was seen in the percentage of subjects who developed protective levels of anti-HBs (≤10 mIU/mL) with three 40-μg doses of S subunit vaccine versus the other groups. One hundred percent of the 40-μg dose group developed protective anti-HBs titers. No difference in adverse effects was noted.

Original language	English
Pages (from-to)	678-681
Number of pages	4
Journal	Journal of Infectious Diseases
Volume	175
Issue number	3
DOIs	https://doi.org/10.1093/infdis/175.3.678
State	Published - 1997

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/infdis/175.3.678

Fingerprint

Dive into the research topics of 'A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S₁, and pre- S₂ particles for revaccination of healthy adult nonresponders'. Together they form a unique fingerprint.

Cite this

Bertino, J. S., Tirrell, P., Greenberg, R. N., Keyserling, H. L., Poland, G. A., Gump, D., Kumar, M. L., & Ramsey, K. (1997). A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S₁, and pre- S₂ particles for revaccination of healthy adult nonresponders. Journal of Infectious Diseases, 175(3), 678-681. https://doi.org/10.1093/infdis/175.3.678

@article{b459e939fb444f798f2a7829f60a5e68,

title = "A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre- S2 particles for revaccination of healthy adult nonresponders",

abstract = "The efficacy of 10-μg and 40-μg hepatitis B vaccines was compared with that of an investigational vaccine containing pre-S1, pre-S2, and S subunit particles (mixed particle vaccine) in inducing protective anti-hepatitis B surface antigen (anti-HBs) concentrations in 46 otherwise healthy persons who previously did not develop measurable levels of antibodies to at least one complete course of vaccine. A statistically significant difference was seen in the percentage of subjects who developed protective levels of anti-HBs (≤10 mIU/mL) with three 40-μg doses of S subunit vaccine versus the other groups. One hundred percent of the 40-μg dose group developed protective anti-HBs titers. No difference in adverse effects was noted.",

author = "Bertino, {Joseph S.} and Paul Tirrell and Greenberg, {Richard N.} and Keyserling, {Harry L.} and Poland, {Gregory A.} and Dieter Gump and Kumar, {Mary Lou} and Keith Ramsey",

year = "1997",

doi = "10.1093/infdis/175.3.678",

language = "English",

volume = "175",

pages = "678--681",

number = "3",

}

Bertino, JS, Tirrell, P, Greenberg, RN, Keyserling, HL, Poland, GA, Gump, D, Kumar, ML & Ramsey, K 1997, 'A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S₁, and pre- S₂ particles for revaccination of healthy adult nonresponders', Journal of Infectious Diseases, vol. 175, no. 3, pp. 678-681. https://doi.org/10.1093/infdis/175.3.678

A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S₁, and pre- S₂ particles for revaccination of healthy adult nonresponders. / Bertino, Joseph S.; Tirrell, Paul; Greenberg, Richard N. et al.
In: Journal of Infectious Diseases, Vol. 175, No. 3, 1997, p. 678-681.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre- S2 particles for revaccination of healthy adult nonresponders

AU - Bertino, Joseph S.

AU - Tirrell, Paul

AU - Greenberg, Richard N.

AU - Keyserling, Harry L.

AU - Poland, Gregory A.

AU - Gump, Dieter

AU - Kumar, Mary Lou

AU - Ramsey, Keith

PY - 1997

Y1 - 1997

N2 - The efficacy of 10-μg and 40-μg hepatitis B vaccines was compared with that of an investigational vaccine containing pre-S1, pre-S2, and S subunit particles (mixed particle vaccine) in inducing protective anti-hepatitis B surface antigen (anti-HBs) concentrations in 46 otherwise healthy persons who previously did not develop measurable levels of antibodies to at least one complete course of vaccine. A statistically significant difference was seen in the percentage of subjects who developed protective levels of anti-HBs (≤10 mIU/mL) with three 40-μg doses of S subunit vaccine versus the other groups. One hundred percent of the 40-μg dose group developed protective anti-HBs titers. No difference in adverse effects was noted.

AB - The efficacy of 10-μg and 40-μg hepatitis B vaccines was compared with that of an investigational vaccine containing pre-S1, pre-S2, and S subunit particles (mixed particle vaccine) in inducing protective anti-hepatitis B surface antigen (anti-HBs) concentrations in 46 otherwise healthy persons who previously did not develop measurable levels of antibodies to at least one complete course of vaccine. A statistically significant difference was seen in the percentage of subjects who developed protective levels of anti-HBs (≤10 mIU/mL) with three 40-μg doses of S subunit vaccine versus the other groups. One hundred percent of the 40-μg dose group developed protective anti-HBs titers. No difference in adverse effects was noted.

UR - http://www.scopus.com/inward/record.url?scp=0031029869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031029869&partnerID=8YFLogxK

U2 - 10.1093/infdis/175.3.678

DO - 10.1093/infdis/175.3.678

M3 - Article

C2 - 9041342

AN - SCOPUS:0031029869

SN - 0022-1899

VL - 175

SP - 678

EP - 681

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 3

ER -